InsiderInsights.com Daily Round Up 12/29/14: REGN, VRML, OAS, PTBI

|
Includes: ABEO, ADBE, BH-OLD, CRM, FMD, GD, GHC, ILIU, JAZZ, KERX, LII, NMBL, OAS, OHAI, REGN, SKBI, SYK, VRML, XLRN
by: InsiderInsights

Summary

Tables of the top insider purchases and sales filed with the SEC on 12/29/14, based on dollar value.

Dollar values often do not equate with significance when it comes to insider trades.

Proprietary Insider Company Ratings are relayed to clarify significance.

Dollar value is only one metric to assess the significance of an insider transaction, but when high dollar value intersects with significance it spotlights a stock investors should take the time to consider. InsiderInsights Daily Round Up articles are intended as initial research tools, so investors can separate real insider investment intelligence from time-wasting noise.

Click the Company Name links in the tables below to analyze a company's or insider's full insider history. Also feel free to email us with any questions on our proprietary insider data, Insider Filer Statistics, and Insider Company Ratings.

On Today's Tables:

Insider trades were rated Significant at :

  • Vermillion (NASDAQ:VRML), and;
  • Regeneron Pharm (NASDAQ:REGN).

Insider trades were rated Nearly Significant at:

  • Plasmatech Biopharmaceuticals (PTBI);
  • Oasis Petroleum (NYSE:OAS), and;
  • Graham Holdings (NYSE:GHC).

Insider trades were considered Insignificant at:

  • Skystar Bio Pharmaceutical (NASDAQ:SKBI);
  • Oha Investment (NASDAQ:OHAI);
  • Interleukin Genetics (OTCQB:ILIU);
  • Biglari (NYSE:BH-OLD);
  • Acceleron Pharma (NASDAQ:XLRN);
  • Stryker (NYSE:SYK);
  • Lennox Intl (NYSE:LII);
  • Keryx Biopharmaceuticals (NASDAQ:KERX);
  • Jazz Pharm (NASDAQ:JAZZ);
  • Salesforce Com (NYSE:CRM), and;
  • Adobe Systems (NASDAQ:ADBE).

There is a Conflicted Insider Signal (both purchases & sales) at:

  • Nimble Storage (NYSE:NMBL);
  • General Dynamics (NYSE:GD), and;
  • First Marblehead (NYSE:FMD).
Insider Purchases
#: Filer Name Insider Titles Company Name Ticker Trans
Type
Dollar Value
1 Sanofi BO Regeneron Pharm REGN B $79,215,640
2 Biglari Sardar CB,CEO,BO Biglari BH AB $2,858,174
3 Growth Equity Opps Fd BO Interleukin Genetics ILIU JB* $1,992,857
4 Schuler Jack W BO Vermillion VRML JB* $1,855,208
5 Second Curve Capital BO First Marblehead FMD B $1,768,420
6 Feinberg Larry N BO Vermillion VRML JB* $1,400,000
7 Gregory John M BO Skystar Bio Pharmaceutical SKBI B $303,024
8 August Glenn R DIR Oha Investment OHAI JB* $252,664
9 Swanson Douglas E Jr DIR Oasis Petroleum OAS B $252,000
10 Jeffrey B Davis DIR Plasmatech Biopharmaceuticals PTBI JB* $250,000

Source: InsiderInsights.com | Key to Insider Title and Trans Type Codes :
B =Open-market Buy; AB=10b5-1 (automatic) Buy; JB*=Buy indicated as being open-market, but not confirmed by trading price range and volume for the session.

Insider Sales
#: Filer Name Insider Titles Company Name Ticker Trans
Type
Dollar Value
1 Graham Donald CEO,CB,BO Graham Holdings GHC S $56,264,624
2 Valueact DIR Adobe Systems ADBE S $52,284,000
3 Mulligan Seamus DIR Jazz Pharm JAZZ AS $8,169,892
4 Bentsur Ron CEO,DIR Keryx Biopharm KERX JS*,S $4,738,899
5 Stryker Ronda E DIR Stryker SYK AS,JS* $2,660,994
6 Chabraja Nicholas DIR General Dynamics GD S $2,334,943
7 Benioff Marc CB,CEO Salesforce Com CRM AS $2,272,168
8 Mehta Varun VP,DIR Nimble Storage NMBL AS $2,230,738
9 Kania Edwin M Jr DIR Acceleron Pharma XLRN S $2,065,300
10 Bluedorn Todd M CB,CEO Lennox Intl LII AS $2,042,191

InsiderInsights.com | Key to Insider Title and Trans Type Codes :
S =Open-market Sale; AS=10b5-1 (automatic) Sale; JS*=Sale indicated as being open-market, but not confirmed by trading price range and volume for the session.

If you're interested in the insider history of a stock not shown here, you can search by ticker.

Did you miss our Previous Daily Round Up?

Disclosure: The author is long REGN.

The author wrote this article themselves, and it expresses their own opinions. The author is not receiving compensation for it (other than from Seeking Alpha). The author has no business relationship with any company whose stock is mentioned in this article.

Editor's Note: This article covers one or more stocks trading at less than $1 per share and/or with less than a $100 million market cap. Please be aware of the risks associated with these stocks.